Biotech · Private company
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Track this companyFree. Adds DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company to your Dealase workspace and tells you when its record changes.
Clinical trials80 recruiting or active
Pipeline programs22From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline22
- DC-806Phase 2 · Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- LY4100511Phase 2 · Plaque PsoriasisClinicalTrials.gov · fetched Nov 12, 2026
- [14C]-LY4100511 (DC-853)Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- [14C]-LY4100511 (DC-853) Administered oral dosePhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- CarbamazepinePhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- CarbamazepinePhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- DC-806Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- DC-806Phase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- DigoxinPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- DigoxinPhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- FluconazolePhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- ItraconazolePhase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
- ItraconazolePhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- LY4100511 (DC-853)Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- LY4100511 (DC-853) Dose 1Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- LY4100511 (DC-853) Dose 2Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- LY4100511 (DC-853) Dose 3Phase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- MidazolamPhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- MidazolamPhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- RepaglinidePhase 1 · HealthyClinicalTrials.gov · fetched Nov 12, 2026
- RepaglinidePhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
- RosuvastatinPhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque PsoriasisPHASE2 · COMPLETED · started Oct 25, 2024ClinicalTrials.gov NCT06602219 · fetched Nov 12, 2026
- A Study of LY4100511 (DC-853) Mass Balance and Absolute Bioavailability of LY4100511 in Healthy Male ParticipantsPHASE1 · COMPLETED · started Aug 23, 2024ClinicalTrials.gov NCT06627088 · fetched Nov 12, 2026
- A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy ParticipantsPHASE1 · COMPLETED · started Jul 16, 2024ClinicalTrials.gov NCT06503679 · fetched Nov 12, 2026
- A Study to Assess LY4100511 (DC-853) in Healthy Adult ParticipantsPHASE1 · COMPLETED · started Apr 3, 2024ClinicalTrials.gov NCT06345794 · fetched Nov 12, 2026
- A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian ParticipantsPHASE1 · COMPLETED · started Mar 19, 2024ClinicalTrials.gov NCT06311656 · fetched Nov 12, 2026
- A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy ParticipantsPHASE1 · COMPLETED · started Oct 16, 2023ClinicalTrials.gov NCT06092931 · fetched Nov 12, 2026
- A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult ParticipantsPHASE1 · COMPLETED · started Aug 8, 2023ClinicalTrials.gov NCT05994807 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque PsoriasisPHASE2 · COMPLETED · started May 2, 2023ClinicalTrials.gov NCT05896527 · fetched Nov 12, 2026